Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

What Documentation Is Required for Cannabis Access in Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

While cannabis-based medicinal products (CBPMs) are legal in the UK, dementia is not an approved indication for these treatments. However, if cannabis is prescribed off-label for a person with dementia, strict documentation and regulatory procedures are required to ensure compliance with NHS, NICE, and Home Office guidelines. 

Can medical cannabis be accessed legally for women’s health?

Legal Framework for Cannabis Access 

In the UK, cannabis-based products are classified as Schedule 2 controlled drugs under the Misuse of Drugs Regulations 2001 (UK Legislation). This means that cannabis products can only be prescribed by a specialist doctor registered with the General Medical Council (GMC) and listed on the Specialist Register. The prescription must meet strict documentation requirements for both safety and legal compliance. 

According to NHS England, CBPM prescriptions must detail: 

  • Formulation (e.g., oil, spray, capsule) 
  • Dosage and administration route 
  • Prescriber details and specialist justification 

Documentation Requirements for Dementia Care 

When a person with dementia is prescribed cannabis for an off-label condition, the following documentation protocols are essential: 

  1. Patient’s Clinical History 
    The prescriber must include a detailed clinical history, outlining any previous treatments attempted, including whether conventional medications have failed, and the reasons for considering cannabis-based treatment. 
  1. Informed Consent or Best-Interest Decisions 
    The Mental Capacity Act 2005 requires that patients with the capacity to consent must be fully informed of the treatment’s potential benefits and risks. For those who lack capacity, best-interest decisions must be made with family involvement and documented accordingly. Mental Capacity Act 2005. 
  1. Ongoing Monitoring and Review 
    According to NICE SC1 and CQC guidelines, all cannabis prescriptions must be monitored for efficacy and side effects. This includes regular documentation on: 
  1. Cognitive function 
  1. Behavioural changes 
  1. Possible adverse effects (e.g., sedation, confusion) 

Monitoring must be recorded in the Medication Administration Record (MAR) and reviewed by the prescribing specialist on an ongoing basis. 

  1. Controlled Drugs Register 
    Cannabis prescriptions must be stored securely, in compliance with controlled drugs protocols. Care facilities and residential homes are required to maintain a controlled drugs register, which records details of each cannabis prescription, including: 
  1. Batch number 
  1. Expiry date 
  1. Witnessed administration details 

Clinical Bottom Line 

  • Cannabis is not approved for dementia symptoms, and any prescription must be off-label. 
  • Detailed clinical history, informed consent or best-interest decisions, and ongoing monitoring are required for legal and ethical compliance. 
  • Cannabis prescriptions must be securely stored, documented, and monitored under controlled drug protocols. 

Educational Context: AlleviMed 

AlleviMed provides educational resources about the regulated use of cannabis in the UK. It helps clinicians and carers navigate the complex legal and documentation requirements for CBPM prescriptions in dementia care. 

Takeaway 

For a person with dementia to access cannabis-based products, specialist prescribing is required, along with strict documentation for legal and safety compliance. Ongoing monitoring, informed consent, and controlled-drug protocols must be carefully followed to ensure both safety and regulatory adherence. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories